Jean-Jacques Body1. 1. Department of Medicine, CHU Brugmann, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. jean-jacques.body@chu-brugmann.be
Abstract
PURPOSE OF REVIEW: To provide a critical review of recent trials of bone resorption inhibitory drugs (bisphosphonates and denosumab) for the treatment and the prevention of bone metastases in solid tumors. RECENT FINDINGS: The bisphosphonate zoledronic acid is now part of the standard treatment for metastatic bone disease. Comparative trials in this setting between zoledronic acid and denosumab have shown superior (in breast and in prostate cancer) or noninferior (in other solid tumors) skeletal-related event-prevention activity for denosumab. Osteonecrosis of the jaw is the most important side-effect of both compounds. Recent data also indicate the potential of zoledronic acid to reduce the recurrence rate in breast cancer. SUMMARY: Much progress has been accomplished for the treatment of tumor bone disease with bone resorption inhibitory drugs. Advances are now awaited in the setting of prevention of bone metastases.
PURPOSE OF REVIEW: To provide a critical review of recent trials of bone resorption inhibitory drugs (bisphosphonates and denosumab) for the treatment and the prevention of bone metastases in solid tumors. RECENT FINDINGS: The bisphosphonatezoledronic acid is now part of the standard treatment for metastatic bone disease. Comparative trials in this setting between zoledronic acid and denosumab have shown superior (in breast and in prostate cancer) or noninferior (in other solid tumors) skeletal-related event-prevention activity for denosumab. Osteonecrosis of the jaw is the most important side-effect of both compounds. Recent data also indicate the potential of zoledronic acid to reduce the recurrence rate in breast cancer. SUMMARY: Much progress has been accomplished for the treatment of tumor bone disease with bone resorption inhibitory drugs. Advances are now awaited in the setting of prevention of bone metastases.
Authors: Bhavani Krishnan; Thomas L Smith; Purnima Dubey; Michael E Zapadka; Frank M Torti; Mark C Willingham; E Ann Tallant; Patricia E Gallagher Journal: Prostate Date: 2012-05-29 Impact factor: 4.104
Authors: R Rizzoli; J J Body; A DeCensi; A De Censi; J Y Reginster; P Piscitelli; M L Brandi Journal: Osteoporos Int Date: 2012-01-20 Impact factor: 4.507
Authors: Zhiqing Xing; Bryan S Moon; Robert L Satcher; Patrick P Lin; Valerae O Lewis Journal: Clin Orthop Relat Res Date: 2013-01-30 Impact factor: 4.176
Authors: Omer Raheem; Anna A Kulidjian; Christina Wu; Young B Jeong; Tomonori Yamaguchi; Kristen M Smith; Daniel Goff; Heather Leu; Sheldon R Morris; Nicholas A Cacalano; Koichi Masuda; Catriona H M Jamieson; Christopher J Kane; Christina A M Jamieson Journal: J Transl Med Date: 2011-10-28 Impact factor: 5.531
Authors: Sonia Vallet; Muhammad Hasan Bashari; Feng-Juan Fan; Stefano Malvestiti; Andreas Schneeweiss; Patrick Wuchter; Dirk Jäger; Klaus Podar Journal: PLoS One Date: 2016-03-02 Impact factor: 3.240